Clinical trials: Neoadjuvant Chemoimmunotherapy
Triple Negative Breast Cancer
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine (PCV) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative…
- Trial name
- NCT07300475
- Testing
- Paclitaxel, Carboplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Cervical Cancer, Neoadjuvant Chemoimmunotherapy
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer…
- Conditions
- Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
- Trial name
- NCT06289751
- Testing
- Cadonilimab, Paclitaxel-albumin, Cisplatin
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
In this study, participants will be randomly assigned to either the experimental group or the control group. The experimental group will first receive SBRT (6Gy*3 fractions) to treat the primary tumor and metastatic lymph nodes.
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)
- Trial name
- NCT06861712
- Testing
- SBRT, Docetaxel, Cisplatin, Toripalimab, Radical resection surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
SBRT
SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
In resectable locally advanced oral cavity cancer and oropharyngeal cancer, SBRT with the total dose of 18 Gy by three fractions will be delivered to the primary tumor and metastatic lymph nodes every other day.
- Trial name
- NCT06219980
- Testing
- SBRT+chemoimmunotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Gastroesophageal Junction, Gastric / Gastroesophageal Junction Adenocarcinoma
Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma
This study is a prospective, multicenter, single-arm clinical trial. The study intends to enroll patients with pathologically or cytologically confirmed resectable locally advanced gastroesophageal junction tumors (cT2N+M0 and…
- Conditions
- Gastroesophageal Junction, Gastric / Gastroesophageal Junction Adenocarcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT07092449
- Testing
- Neoadjuvant chemo-immunotherapy
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the performance of a CT/PET/ WSI-based deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy, Complete Pathological Response
- Trial name
- NCT05925751
- Testing
- CT/PET/WSI-based Deep Learning Signature
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Limited Stage Small Cell Lung Cancer
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
To compare the efficiency between surgery and radiotherapy after SHR-1316 (Adebrelimab)and platinum-containing doublet induction therapy for limited-stage small cell lung cancer
- Trial name
- NCT05496166
- Testing
- chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Esophageal Squamous Cell Carcinoma (ESCC)
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Patients with esophageal cancer still face a high risk of recurrence after receiving neoadjuvant chemoradiotherapy (nCRT) combined with radical surgery, especially for those who do not achieve pathological complete response…
- Trial name
- NCT07067450
- Testing
- Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab), Observation
- Volunteers
- 98 people
- Sponsor
- Sichuan University
Deep Learning Model, Pathological Complete Response
Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy
This study presents the development and validation of an artificial intelligence (AI) prediction system that utilizes pre-neoadjuvant immunotherapy plain scans and enhanced multimodal CT scans to extract deep learning features.
- Conditions
- Deep Learning Model, Pathological Complete Response, Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06285058
- Testing
- No interventions
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
HER2-positive Breast Cancer, ER-positive Breast Cancer
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.
- Trial name
- Neohttp (NCT02345772)
- Testing
- fulvestrant 500 mg, Docetaxel, Trastuzumab (H, 8mg/kg
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Western Regional Medical Center
NSCLC
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
This study evaluates the preliminary efficacy and safety of adjuvant therapy with liquid tumor-infiltrating lymphocytes (L-TIL) in combination with tislelizumab in patients with resectable stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07330037
- Testing
- L-TIL cells injection, Tislelizumab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophagus Cancer
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy.
- Trial name
- NCT07063901
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Central South University
Non Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this study is to evaluate the safety and efficacy of Camrelizumab in combination with platinum doublet neoadjuvant chemotherapy before surgery [neoadjuvant phase], followed by Camrelizumab alone after surgery…
- Trial name
- NEOSUN (NCT04943029)
- Testing
- Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA)…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm
- Trial name
- NeoCamre-HN (NCT07400094)
- Testing
- Camrelizumab, Paclitaxel, carboplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Early Triple-Negative Breast Cancer
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
This multicenter phase II study evaluates a de-escalation strategy of neoadjuvant chemo-immunotherapy in patients with stage II early triple-negative breast cancer and tumor-infiltrating lymphocytes (TILs) ≥ 30%.
- Trial name
- DECREASE (NCT07857486)
- Testing
- Pembrolizumab
- Volunteers
- 84 people
- Sponsor
- Institut Paoli-Calmettes